Overview

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborators:
Pediatric Heart Network
Pfizer
Treatments:
Apixaban
Calcium heparin
Dalteparin
Enoxaparin
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin
Vitamin K
Vitamins
Warfarin